ORYZON receives approval in the United Kingdom to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

MADRID, SPAIN and CAMBRIDGE MA.

• This trial was approved in the previous weeks in Spain and France

• This approval concludes the regulatory start of this trial in Europe

• This is the second Phase II study in CNS with the drug

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that it has received approval of a Clinical Trial Application (CTA), the European IND equivalent, from the Medicines & Healthcare products Regulatory Agency (MHRA) and also from the Ethics Committee to conduct a Phase IIa clinical study with ORY-2001 in patients of Alzheimer’s disease (AD) in the UK. The trial had been previously approved in Spain and France. With this approval, the trial is now fully operationally deployed upon receipt from the corresponding regulatory authorities of all initially scheduled approvals.

Click here to see the full Press Release